Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Ubiome Gut EXPLORER : 10% OFF
Join/Watch the weekly
TMAU UP Podcasts

Videos : TMAU stories

MEBO Map Testing & Meetups

Full details :
want listed ? contact
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect

£ 943.03/GBP
$ 568.00/USD

TOTAL at today's ROE
£0.80/GBP = $1.00/USD

£1,398.07 = $1,745.14



Your currency will be automatically converted to USD or GBP by PayPal.

Option: pay with your credit card instead of PayPal account by clicking on either Donate button above.

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed

Subscribe to Blog

Enter your email address:

Delivered by FeedBurner

You will be sent a verification email

Subscribe in a reader

Blog Archive

Wednesday, September 19, 2018

MEBO chat with NIH ORDR office :details to follow

Details will follow soon of :
MEBO web conference with NIH ORDR dept team.
Tue 18th Sept

Info given after the chat :

Thank you for speaking with us earlier today. In follow-up to our conversation, here are links to some of the programs and resources we spoke about.

RDCRN (Rare Disease Clinical Research Network) Funding Opportunity Announcement -

Toolkit for Patient Focused Therapy Development -

R13 Grants (Support for Conferences and Scientific Meetings) -

All of Us Research Program -

Registries Program (RaDaR):

Additional registry information outside of NIH:

NORD (National Organization Rare Disease) -
Sanford CoRDS (Coordination of Rare Diseases at Sanford) -

Additional info given :

Thank you for the time to talk to us about TMAU yesterday.

In terms of drug development for TMAU, given the available knowledge of the TMA metabolism, it seems possible that small molecules could be developed to modulate TMA levels.

The attached PDF entitled TMA inhibitor is an example that I found.

You may have seen this, but It turns out that the same approach has implications for treating heart disease, so there is already drug development ongoing

There may be other labs or companies working in the same area, so this is not intended to be a complete list.

Along the same lines, another possible therapeutic strategy that is worth considering would be breaking down or trapping TMA.

While gene therapy to the liver is theoretically possible, it seems unlikely at the moment given the serious risks of gene therapy, and since TMAU is not a life threatening disease.

An alternative that could be considered is using genetically modified microorganisms in the gut to do the same things.

These links discuss some examples of that strategy.

Here are two companies working in this area that I know of;
there may well be more

As I mentioned yesterday, this information is not an endorsement of any company; just some ideas for you to consider and discuss with your scientific and medical advisors.

get New Posts by EMAIL : Enter your email address :

A EURORDIS and NORD Member Organization


Post a Comment